PRM-151 (Zinpentraxin Alfa)

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Idiopathic Pulmonary Fibrosis

Phase 3

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

TerminatedNCT04552899

Hoffmann-La RocheIdiopathic Pulmonary Fibrosis

Start: 2021-03-19End: 2023-02-10Updated: 2024-04-18

A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

TerminatedNCT04594707

Hoffmann-La RocheIdiopathic Pulmonary Fibrosis

Start: 2021-08-30End: 2023-02-10Updated: 2024-05-16

Related Papers

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial

American Journal of Respiratory and Critical Care Medicine2024-02-1437 citations

A formula for predicting emphysema extent in combined idiopathic pulmonary fibrosis and emphysema.

2024-01-182 citations

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

Respiratory Research2022-05-2128 citations

Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study

2021-09-051 citations

Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program

2021-09-05

Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) for Idiopathic Pulmonary Fibrosis: Study Design of STARSCAPE, A Phase III Randomized Double Blind Placebo Controlled Trial

2021-05-011 citations